DiscoveryProbe™ FDA-approved Drug Library: Structured Resource for High-Throughput Drug Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) contains 2,320 bioactive compounds that have passed regulatory approval by agencies such as the FDA, EMA, and PMDA, ensuring clinical relevance and safety profiles for each molecule. The library is provided in ready-to-screen 10 mM DMSO solutions, supporting rapid deployment in high-throughput screening (HTS) and high-content screening (HCS). The collection covers diverse mechanisms of action, including enzyme inhibition, receptor modulation, and signal pathway regulation. Empirical evidence demonstrates its utility in drug repositioning and novel target identification, as shown by recent studies in oncology and metabolic disease models (He et al., 2023). The library's stability and flexible formats (96-well plates, deep-well plates, 2D-barcoded tubes) facilitate workflow integration for translational and basic research settings.

Biological Rationale

Drug discovery increasingly relies on clinically validated compound libraries to accelerate the identification of novel therapeutics. FDA-approved drug libraries, such as DiscoveryProbe™ (L1021), provide a regulatory-vetted set of molecules with known safety and pharmacokinetic profiles (product page). This enables researchers to focus on drug repositioning and target deconvolution, leveraging existing clinical data to minimize translational risk. The use of such libraries in HTS and HCS platforms increases the efficiency of identifying candidate compounds for diseases with unmet medical needs, such as cancer and neurodegenerative disorders (internal: Pyronaridine-Tetraphosphate—which details curation but does not address mechanism-of-action breadth as in this article). Drug repositioning via FDA-approved collections bypasses early safety hurdles, accelerating preclinical and clinical pipelines (internal: Nafamostat Mesylate—which focuses on workflow translation, whereas this article details chemical diversity and regulatory scope).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library (L1021) encompasses a wide range of pharmacological mechanisms:

• Receptor Agonists and Antagonists: Compounds modulate GPCRs, nuclear receptors, and ion channels, affecting cellular signaling cascades.
• Enzyme Inhibitors: Molecules targeting kinases, proteases, and metabolic enzymes are included, supporting target validation and pathway interrogation.
• Ion Channel Modulators: Agents affecting voltage- and ligand-gated channels are represented, enabling screens for neurodegenerative and cardiovascular indications.
• Signal Pathway Regulators: The library contains compounds acting on Wnt, PI3K/Akt, MAPK, and apoptotic pathways, as shown by doxorubicin and metformin among others (He et al., 2023).

Each compound is provided as a 10 mM solution in DMSO, ensuring compatibility with automated liquid handling and minimizing solubility variability. Storage at -20°C provides 12 months of stability, while -80°C extends stability to 24 months. The formulations are suitable for both cell-based and biochemical assays (product documentation).

Evidence & Benchmarks

• A BRET-based high-throughput screen using an FDA-approved drug library identified repurposing candidates (terfenadine, penfluridol, lomitapide) that disrupt 14-3-3:BAD interactions in colorectal cancer models (He et al., 2023).
• The DiscoveryProbe™ FDA-approved Drug Library supports HTS and HCS, validated by a Z’-score of 0.52 in BRET-based assays, indicating reliable assay performance (He et al., 2023).
• Compounds are clinically approved by agencies including FDA, EMA, HMA, CFDA, and PMDA or are pharmacopeia-listed, as specified in the official product documentation (product page).
• Solutions remain stable for 12 months at -20°C and up to 24 months at -80°C, as verified by internal QC protocols (product documentation).
• Drug repositioning screens using this library have enabled rapid identification of pro-apoptotic agents with minimal systemic toxicity in cell-based models (He et al., 2023).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is applied in:

• High-throughput screening for cancer therapeutics, including colorectal and hematological malignancies.
• Drug repositioning for neurodegenerative diseases, metabolic disorders, and infectious diseases (internal: Hyperfluor—this article adds benchmark stability and regulatory context not explored there).
• Identification of novel pharmacological targets and validation of signaling pathway modulators.
• Mechanistic studies in disease models, leveraging known clinical safety data.

Common Pitfalls or Misconceptions

• The library does not contain investigational or preclinical compounds; all entries are clinically approved or pharmacopeia-listed.
• Not all compounds are suitable for in vivo use directly from the provided DMSO solution; further formulation may be required.
• Resistance profiles and off-target effects observed in clinical contexts may still limit utility in novel indications.
• The presence of a compound in the library does not guarantee efficacy in all models or disease systems.
• Storage above -20°C or repeated freeze-thaw cycles can compromise compound integrity and screening results.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is designed for compatibility with automated screening platforms. Each compound is pre-dissolved at 10 mM in DMSO and aliquoted in user-specified formats (96-well microplates, deep well plates, 2D-barcoded screw-top tubes) to support flexible assay design. Shipping is performed on blue ice for evaluation samples and at room temperature or on blue ice upon request for larger sizes. The solutions remain stable for 12 months at -20°C and 24 months at -80°C, minimizing the risk of degradation during storage (product documentation).

For HTS, typical screening concentrations range from 1–10 µM in final assay conditions, with DMSO concentrations kept below 0.5% v/v to avoid cell toxicity. Researchers are advised to validate compound activity in their model system and consider known pharmacokinetic properties from clinical data. The L1021 kit integrates seamlessly into existing target identification, signal pathway analysis, and drug repositioning pipelines.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) offers a stable, regulatory-compliant, and mechanistically diverse set of compounds for drug discovery workflows. Empirical evidence supports its use in high-throughput and high-content screening, with proven applications in oncology, metabolic disease, and neurodegeneration (He et al., 2023). The library’s integration with automated platforms, robust stability, and regulatory breadth make it an indispensable tool for translational and basic research teams. As drug repositioning and target deconvolution strategies advance, compound collections like DiscoveryProbe™ are expected to accelerate the identification of novel therapeutics and the translation of mechanistic insights into clinical innovation.